3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Lung Neoplasms
2
Kidney Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Recurrence
1
Ovarian Neoplasms
1
Metastatic Urothelial Cancer
1
Melanoma
1
Lung Diseases
1
Glioblastoma
1
Esophageal Neoplasms
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Advanced Solid Tumors
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
pembrolizumab
22
Nivolumab
14
enfortumab vedotin
13
Gemcitabine
11
Specimen Handling
9
Magnetic Resonance Spectroscopy
9
Cisplatin
8
Carboplatin
8
sacituzumab govitecan
6
avelumab
6
Docetaxel
6
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
CTLA-4 Antigen
3
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Immunoglobulin G
2
Fluorouracil
2
Disulfides
2
ALT-803
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
zimberelimab
×
90 days
×
Clear all
No trials found.